A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...
In our Case of the Week, the Federal Circuit revived Novartis’s US Patent No. 8,101,659 by reversing the district court’s decision which found the patent invalid for lack of written description. The ...